Hsbc Holdings PLC Has $1.88 Million Position in Embecta Corp. $EMBC

Hsbc Holdings PLC boosted its position in Embecta Corp. (NASDAQ:EMBC) by 1,268.6% in the first quarter, Holdings Channel.com reports. The firm owned 212,491 shares of the company’s stock after purchasing an additional 196,965 shares during the quarter. Hsbc Holdings PLC’s holdings in Embecta were worth $1,882,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after buying an additional 6,224 shares during the last quarter. Wexford Capital LP bought a new position in Embecta in the 3rd quarter valued at approximately $94,000. Humankind Investments LLC acquired a new stake in Embecta during the 2nd quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd acquired a new stake in Embecta during the 3rd quarter worth approximately $115,000. 93.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

EMBC has been the topic of a number of research reports. BTIG Research lowered shares of Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Bank of America dropped their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday, May 18th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Weiss Ratings cut shares of Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $11.00.

Embecta Price Performance

Shares of EMBC stock opened at $3.29 on Monday. The business’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $7.25. Embecta Corp. has a one year low of $2.77 and a one year high of $15.55. The stock has a market capitalization of $195.20 million, a PE ratio of 1.73 and a beta of 0.83.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same quarter in the previous year, the business posted $0.70 EPS. The firm’s revenue for the quarter was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, research analysts expect that Embecta Corp. will post 1.62 earnings per share for the current year.

Embecta Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Thursday, May 28th were given a dividend of $0.01 per share. The ex-dividend date was Thursday, May 28th. This represents a $0.04 annualized dividend and a dividend yield of 1.2%. Embecta’s dividend payout ratio is 2.11%.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Neutral Sentiment: Multiple law firms renewed reminders that a securities class action has been filed against Embecta Corp. and that investors who bought shares between November 25, 2025 and May 4, 2026 face an August 17, 2026 lead-plaintiff deadline. Article: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
• Neutral Sentiment: Hagens Berman said it is investigating alleged securities law violations following the lawsuit, which claims Embecta misrepresented the commercial stability of its insulin pen needle business. Article: EMBC Alert: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation
• Neutral Sentiment: Other firms, including Rosen, Faruqi & Faruqi, The Gross Law Firm, Bragar Eagel & Squire, Kaplan Fox, Pomerantz, Bernstein Liebhard, and Bleichmar Fonti & Auld, issued similar class-action notices, increasing visibility around the stock but not providing new operational information. Article: EMBC Fraud Notification: Embecta Sued for Fraud Over Misrepresentations about its Insulin Pen Issues
• Neutral Sentiment: Embecta’s reported short interest was listed at 0 shares, offering no sign of meaningful bearish positioning based on the latest update. Article: DEADLINE ALERT for EMBC, FSLR, GTM, BTU

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.